Stocks to Buy Today - Stock Message Board, Discussion Forum, Blog
Hemispherx Biopharma, Inc. HEB
Hemispherx Biopharma, Inc. (HEB) stock is rising on no news. Back in the summer, HEB was trading at $4 due to speculation that their Chronic Fatigue Syndrome Drug Ampligen would get approval. Now it almost appears that the drug doesn't even exist.
Anyway, HEB is trading at $1.12 Up 10% in pre market....keep an eye on it
Anyway, HEB is trading at $1.12 Up 10% in pre market....keep an eye on it
Tags: Biopharma, HEB, Hemispherx, Inc., ampligen
Views: 17
Replies to This Discussion
-
Permalink Reply by Ali on -
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), stated that on December 11, 2009, the Company, via its manufacturing subcontractor, in Spokane, WA, submitted comprehensive new data to the regional office of the Food and Drug Administration ("FDA"), Seattle, WA, which Hemispherx management believes demonstrate that certain manufacturing issues noted in earlier pre-approval inspections at the facility have been fully addressed.
do think this news wil lift this stock?
-
Permalink Reply by Michael George on -
I know Carter is going to pump this up again, but wasn't there more issues than just manufacturing? wasn't there something about the drug itself?
- ‹ Previous
- 1
- 2
- Next ›
Like Us on Facebook
Stock Alerts
- Subscribe Via RSS Feed or - Subscribe to Stocks To Buy by Email
Research
Buy Oil Stocks 2012/2013
What Stocks to Buy? Oil prices continue to rise and oil stocks are a good buy for the long term. For oil stock ideas, check out the latest hot shale plays in the US.
Utica Shale
Bakken Shale
Eagle Ford Shale
My Stock Picks for 2012
Upcoming IPO's 2012
Emerging Oil & Gas Fields
© 2012 Created by Stocks To Buy.
